AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04459741 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary salt (Sodium chloride)
Description: Dietary salt used was sodium chloride tablets (from the research consolidated midland corporation division, New York, USA) which participants crashed and put in their food and/or ingested. Each tablet weighed one (1) gram and contained 394 mg of sodium and 606 mg of chloride.
Study NCT04459741 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Dietary salt (Sodium chloride)
Description: Dietary salt used was sodium chloride tablets (from the research consolidated midland corporation division, New York, USA) which participants crashed and put in their food and/or ingested. Each tablet weighed one (1) gram and contained 394 mg of sodium and 606 mg of chloride.
Study NCT02163265 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Patients suffering from Pectus excavatum Pectus carinatum will be treated surgically according to normal procedures
Study NCT01916044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Measure of Uterine Segment by Ultrasound
Study NCT04241471 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: incision and loop drainage
Description: incision and loop drainage utilizing the rolled ring of a sterile glove technique
Study NCT04241471 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: traditional incision and drainage (I&D)
Description: traditional incision and drainage (I\&D)
Study NCT04056897 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-132, 125 mg
Description: IV infusion every 24 weeks in combination with placebo tablet daily. The total duration of blinded therapy is 100 weeks (a total of 5 cycles of therapy BCD-132 in combination with a daily placebo)
Study NCT04056897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriflunomide
Description: 14 mg teriflunomide tablet. Per os. Daily in combination with IV placebo. The total duration of blinded therapy is 100 weeks (a total of 5 cycles of placebo IV therapy in combination with daily administration of teriflunomide)
Study NCT04056897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous infusion in combination with placebo tablet daily. The total duration of blinded therapy is 100 weeks
Study NCT04056897 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-132, 500 mg
Description: IV infusion every 24 weeks in combination with placebo tablet daily. The total duration of blinded therapy is 100 weeks (a total of 5 cycles of therapy BCD-132 in combination with a daily placebo)
Study NCT03631134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: Patients will be gave SGLT2 inhibitor 10mg per day
Study NCT00704288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL184
Description: Gelatin capsules supplied in 25-mg and 100-mg strengths; continuous daily dosing
Study NCT03536559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNM-Au8
Description: CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
Study NCT03536559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is liquid with identical color and taste
Study NCT01055314 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Given IV
Study NCT01055314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01055314 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Given IV
Study NCT01055314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT01055314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT01055314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV
Study NCT01055314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT01055314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01055314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT01951924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)
Study NCT01500291 — intervention group
Intervention type: OTHER
Intervention: 2 courseware databases.
Description: All participant voluntarily response all items in the SST and SAST courseware database.
Study NCT03585829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: at a substitutive dosage
Study NCT03585829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: at a substitutive dosage
Study NCT00727662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iyengar Yoga
Description: The poses and breathing techniques to be used in this study are based on sequences developed by B.K.S. Iyengar for breast cancer survivors who suffer from fatigue. Women will start with simple versions of the poses and progress to more advanced versions over the course of the intervention.
Study NCT00727662 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wellness Seminar Series
Description: The Wellness Seminar Series consists of lectures on key topics, followed by group discussion. This series will focus entirely on cancer survivorship, including sessions on quality of life, side effects of cancer treatment, stress, nutrition and psychosocial issues.
Study NCT01074060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor
Description: Given IV
Study NCT01074060 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study NCT01074060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT01074060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: autologous hematopoietic stem cell transplantation
Study NCT01074060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02895477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hearing aid
Study NCT02973399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNX-5422 plus ibrutinib
Description: SNX-5422 capsule(s) dosed every other day for 21 days out of a 28-day treatment cycle to a total dose of 56 mg/m2 SNX-5422. Subjects will self-administer daily oral ibrutinib in the afternoon at least 8 hours apart from SNX-5422 for 28 days of each cycle.
Study NCT01215045 — intervention group
Intervention type: DEVICE
Intervention: AcrySof ReSTOR Aspheric +4
Description: Implantation with the AcrySof ReSTOR Aspheric +4 Multifocal Intraocular Lens (IOL)
Study NCT03549546 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood samples
Description: Blood samples will be collected in patients undergoing lung cancer surgery:~* before lung cancer surgery,~* the next day lung cancer surgery,~* 3 days after lung cancer surgery. They will be treated in flow cytometry.
Study NCT01951924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological: Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL)
Study NCT04254341 — intervention group
Intervention type: OTHER
Intervention: patients with OSA
Description: Sleep study
Study NCT00606632 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 124-Iodine-cG250 (124I-cG250)
Description: i.v. and PET/CT scan 4+/-2 days after administration
Study NCT00606632 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: CT
Description: contrast enhanced CT scan
Study NCT00784108 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Modulated Imaging (MI)
Description: Modulated Imaging measure effect of Photodynamic therapy treatment
Study NCT00784108 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Photodynamic therapy
Description: Modulated Imaging measure effect of Photodynamic therapy treatment
Study NCT01138787 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Reference spread
Description: Single dose (30 gr) of spread, containing 2250 mg PS
Study NCT01138787 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo spread
Description: Single dose (30 gr) of regular light margarine
Study NCT01138787 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Test spread
Description: Single dose (30 gr) of innovatively processed spread containing 2250 mg PS.
Study NCT02083068 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine PvCS N+C+R
Description: Vaccine PvCS N+C+R 60 mcg, freeze dried powder, Batch n°P0RGB, Exp: 18.10.2015 At month 2 and 6
Study NCT02083068 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine PvCS N+C
Description: Vaccine PvCS N+C 60 mcg, freeze dried powder, Batch n°P0RGA, Exp: 18.10.2015, at month 0
Study NCT02083068 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SSN Montanide ISA-51
Description: SSN Montanide ISA-51 1 mL
Study NCT06188221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: The group with the lidocaine will get a combined injection with a corticosteroid and lidocaine. The dosages depend on the disease.
Study NCT06188221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticoids
Description: The group without the lidocaine will get an injection with only corticosteroids. The corticosteroid dosage depends on the disease and will be the same as for the group with the lidocaine:
Study NCT06188221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticoids
Description: The group without the lidocaine will get an injection with only corticosteroids. The corticosteroid dosage depends on the disease and will be the same as for the group with the lidocaine:
Study NCT03212235 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy
Description: Hypofractionated radiation therapy Total dose: 60 Gy (20 fractions / 3 Gy per fraction)
Study NCT01068483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Study NCT02291991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-E2
Description: Investigational drug(GX-E2 or Placebo) will be administered to healthy volunteers by the intravenous route.
Study NCT00758576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACRYSOF Multifocal Single-piece Intraocular Lens (IOL) Model SN6AD1
Description: Implantation with the AcrySof ReSTOR Intraocular Lens (IOL) Model SN6AD1 following cataract removal.
Study NCT02221804 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 14 days of voluntary step count reduction to no more than 1500 steps/day.
Study NCT04540627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palivizumab
Description: Liquid solution in sterile water for injection (final concentration of 20mg/mL), intravenous infusion, single dose of 8mg/kg or 15mg/kg, administered at a rate of 1mL/min
Study NCT04540627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride 0.9% Solution (Normal Saline), intravenous infusion, single dose of 0mg/Kg, administered at a rate of 1mL/min
Study NCT04540627 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RSV-A Memphis 37b virus
Description: Single Intranasal Virus Dose (challenge dose is approximately 4.5log10 PFU)
Study NCT04540627 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: RSV-A Memphis 37b virus
Description: Single Intranasal Virus Dose (challenge dose is approximately 4.5log10 PFU)
Study NCT01265719 — intervention group
Intervention type: OTHER
Intervention: No intervention other than routine medical care
Description: Subjects continuously treated with Latanoprost for at least one month Latanoprost treatment during the study period.
Study NCT01265719 — intervention group
Intervention type: OTHER
Intervention: No intervention other than routine medical care
Description: Subjects not treated with any topical prostaglandin analogues or continuously treated with topical prostaglandin analogues for less than one month before the baseline examination, and unlikely to be treated with topical prostaglandin analogues during the study period.
Study NCT03455556 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anetumab Ravtansine
Description: Given IV
Study NCT03455556 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT03455556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02530580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg AZD7325
Description: A single 20 mg oral dose of AZD7325
Study NCT02530580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 20 mg AZD7325
Description: A single 20 mg oral dose of AZD7325
Study NCT02530580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A single oral dose
Study NCT02530580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single oral dose
Study NCT03596697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRV431
Description: Single or multiple dose(s) of CRV431
Study NCT03280446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intragen fractional radiofrequency with NeuViVa
Description: The Transcutaneous Fractional Radiofrequency Device (TFRF) is a minimal risk device that is currently cleared by the FDA K142833.The device uses a non-invasive, transepithelial treatment probe to elevate epithelial tissue temperatures to 40-45 oC for the purpose of promoting tissue contracture. Real-time tissue impedance monitoring will be carried out using the treatment probe.
Study NCT04918251 — intervention group
Intervention type: PROCEDURE
Intervention: 128 electrode electroencephalography (EEG)
Description: 128 electrode EEG will be non-invasively recorded from electrodes placed in a montage over the scalp while the participant is resting or performing tasks designed to engage specific cortical motor networks of interest (cognitive, behavioural, motor and sensory)
Study NCT02477956 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3 (Replesta)
Description: vitamin D group receive 2 replesta tablets (100,000 IU/month) of cholecalciferol.
Study NCT02477956 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D
Study NCT00137176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebif
Description: Rebif 44mcg TIW
Study NCT03171376 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root canal treatment and coronal restoration
Description: After primary root canal treatment, Glass Ionomer Cement (Ketac™ Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.
Study NCT04918251 — intervention group
Intervention type: PROCEDURE
Intervention: Transcranial magnetic stimulation (TMS)
Description: Single and paired pulse TMS protocol will be delivered while surface bipolar EMG is recorded over hand muscles to interrogate corticospinal tract function and cortical motor network component functions
Study NCT02572492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction with CAR-CY-DEX and conditioning with carfilzomib and highdose melphalan
Description: All patients entering the study receive four series of CAR-CY-DEX (Cycle 1 with iv carfilzomib 20 mg/sqm on days 1 and 2, and iv carfilzomib 36 mg/sqm on days 8, 9, 15 and 16. Cycle 2 - 4 with iv carfilzomib 36 mg/sqm on days 1, 2, 8, 9, 15 and 16. P.o. cyclophosphamide 300 mg/sqm on days 1, 8 and 15 and p.o. dexamethasone 20 mg on days 1, 2, 8, 9, 15 and 16 in each 28-days series)~Subsequently all patients receive the conditioning regimen:~Iv carfilzomib 27 mg/sqm on day -2 and -1 Iv melphalan 200 mg/sqm on day -2 > 2.0 m CD34+ stem cells/kg body weight on day 0
Study NCT02572492 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Induction with CAR-CY-DEX and conditioning with carfilzomib and highdose melphalan
Description: All patients entering the study receive four series of CAR-CY-DEX (Cycle 1 with iv carfilzomib 20 mg/sqm on days 1 and 2, and iv carfilzomib 36 mg/sqm on days 8, 9, 15 and 16. Cycle 2 - 4 with iv carfilzomib 36 mg/sqm on days 1, 2, 8, 9, 15 and 16. P.o. cyclophosphamide 300 mg/sqm on days 1, 8 and 15 and p.o. dexamethasone 20 mg on days 1, 2, 8, 9, 15 and 16 in each 28-days series)~Subsequently all patients receive the conditioning regimen:~Iv carfilzomib 27 mg/sqm on day -2 and -1 Iv melphalan 200 mg/sqm on day -2 > 2.0 m CD34+ stem cells/kg body weight on day 0
Study NCT02572492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib/dexamethasone maintenance
Description: Maintenance therapy two months after salvage HDT with iv carfilzomib 27 mg/sqm every second week and p.o. dexamethasone 20 mg every second week. The maintenance dose of carfilzomib will be escalated to 56 mg/sqm after 4 weeks provided acceptable side effects.
Study NCT02572492 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Observation without carfilzomib/dexamethasone maintenance
Description: Observation without carfilzomib/dexamethasone maintenance
Study NCT03511222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorolanib
Description: Patients should take vorolanib at approximately the same time every day with food.
Study NCT03511222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Standard of care
Study NCT03511222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Standard of care
Study NCT03726840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fragrance
Description: peppermint, rosemary, and zest/pulp will increase memory recall for navigation and improve reaction times for braking, compared to performance during unscented conditions
Study NCT04622059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: acoustic stimulation
Description: An auditive stimulus was produced by hitting a diapason on an acoustic surface, at a distance of 2-3 cm from the mother's skin (in order to avoid mechanical vibration to reach the fetus) in the area near the fetus' head.~The same procedure was repeated three times, waiting 30 seconds between one stimulus and the following one. The total duration of stimulation was about 2 minutes.
Study NCT02808299 — intervention group
Intervention type: OTHER
Intervention: HBV infection history
Description: HBV infection history or HBV carriers
Study NCT03596697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single Placebo dose
Study NCT03596697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF
Description: Single or multiple dose(s) of TDF
Study NCT01393925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parecoxib
Description: parecoxib 40mg at 30min before the end of surgery, at 8h and 20h after the surgery, intravenously
Study NCT02286206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: One-half baseline dose po bid (or one-third baseline dose po qam and two-thirds baseline dose po qhs at the discretion of the treating clinicians and principal investigator)
Study NCT01055314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposome
Description: Given IV
Study NCT00316290 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Parent Training
Description: Treatment will include behavioral parent training, a course on coping with depression, and cognitive-behavioral therapy targeted at coping with stressful parenting situations. Treatment will include weekly 2-hour sessions for 14 weeks.
Study NCT01049360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium 400 μg / Formoterol 12 μg
Description: Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.
Study NCT01049360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium 400 μg / Formoterol 6 μg
Description: Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.
Study NCT00316290 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Parent Training
Description: Parents will receive behavioral training. Treatment will include weekly 2-hour sessions for 14 weeks.
Study NCT04307888 — intervention group
Intervention type: DEVICE
Intervention: Perclose Proglide (Abbott)
Description: Common Femoral Artery percutaneous access closure by means of Perclose Proglide device